Drug Trial Radar · NCT04626518
Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03)
Last checked: Nov 19, 2026Latest source record: Sep 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
263
Actual
Start
Dec 17, 2020
Primary completion
Jul 23, 2026
Study completion Jul 23, 2026
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Nov 12, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Substudy 03B is part of a larger research study that is testing experimental treatments for renal cell carcinoma (RCC). The larger study is the umbrella study (U03). The goal of substudy 03B is to evaluate the safety and efficacy of experimental combinations of investigational agents in participants with advanced second line plus (2L+) clear cell renal cell carcinoma (ccRCC). This substudy will have two phases: a safety lead-in phase and an efficacy phase. The safety lead-in phase will be used to demonstrate a tolerable safety profile for the combination of investigational agents. There will be no hypothesis testing in this study.
Conditions
- Carcinoma, Renal Cell
Interventions
PembrolizumabBiological
Administered via IV infusion at a dose of 200 mg Q3W or 400 mg Q6W
MK-4830Biological
Administered via IV infusion at a dose of 800 mg Q3W
BelzutifanDrug
Administered via oral tablet at a dose of 120 mg QD
LenvatinibDrug
Administered via oral capsule at a dose of 20 mg QD
Pembrolizumab/QuavonlimabBiological
Administered via IV infusion at a dose of 400 mg/25 mg Q6W
Favezelimab/PembrolizumabBiological
Administered via IV infusion at a dose of 800 mg/200 mg Q3W
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety Lead-in Phase: Number of participants who experience one or more dose-limiting toxicities (DLTs)Time frame: Up to ~21 days
- Safety Lead-in Phase: Number of participants who experience one or more adverse events (AEs)Time frame: Up to ~21 days
- Safety Lead-in Phase: Number of participants who discontinue study treatment due to an AETime frame: Up to ~21 days
- Efficacy Phase: Number of participants who experienced DLTsTime frame: Up to ~21 days
- Efficacy Phase: Number of participants who experience one or more AEsTime frame: Up to ~56 months
- Efficacy Phase: Number of participants who discontinue study treatment due to an AETime frame: Up to ~56 months
- Efficacy Phase: Objective response rate (ORR)Time frame: Up to ~56 months
Locations
51 sites in 13 countries. Site status is shown where the registry gives one.
University of California at San Francisco ( Site 3008)
San Francisco, California
Yale-New Haven Hospital-Yale Cancer Center ( Site 3011)
New Haven, Connecticut
University of Chicago ( Site 3013)
Chicago, Illinois
University of Iowa ( Site 3012)
Iowa City, Iowa
Henry Ford Health System ( Site 3014)
Detroit, Michigan
Laura and Isaac Perlmutter Cancer Center ( Site 3016)
New York, New York
Memorial Sloan Kettering Cancer Center ( Site 3002)
New York, New York
Duke Cancer Institute ( Site 3015)
Durham, North Carolina
UPMC Cancer Center/Hillman Cancer Center ( Site 3017)
Pittsburgh, Pennsylvania
Vanderbilt University Medical Center ( Site 3004)
Nashville, Tennessee
UTSW Medical Center ( Site 3003)
Dallas, Texas
Blacktown Hospital ( Site 3601)
Blacktown, New South Wales, Australia
St George Hospital ( Site 3602)
Kogarah, New South Wales, Australia
Royal Brisbane and Women's Hospital ( Site 3603)
Herston, Queensland, Australia
Austin Health ( Site 3600)
Melbourne, Victoria, Australia
Princess Margaret Cancer Centre ( Site 3101)
Toronto, Ontario, Canada
Jewish General Hospital ( Site 3100)
Montreal, Quebec, Canada
James Lind Centro de Investigacion del Cancer ( Site 4108)
Temuco, Araucania, Chile
CIDO SpA-Oncology ( Site 4106)
Temuco, Araucania, Chile
FALP-UIDO ( Site 4100)
Santiago, Region M. de Santiago, Chile
Bradfordhill-Clinical Area ( Site 4101)
Santiago, Region M. de Santiago, Chile
ONCOCENTRO APYS-ACEREY ( Site 4103)
Viña del Mar, Valparaiso, Chile
Institut De Cancerologie De Lorraine ( Site 3204)
Vandœuvre-lès-Nancy, Ain, France
Institut de cancérologie Strasbourg Europe (ICANS) ( Site 3203)
Strasbourg, Alsace, France
Institut Claudius Regaud ( Site 3200)
Toulouse, Haute-Garonne, France
Gustave Roussy ( Site 3202)
Villejuif, Île-de-France Region, France
Országos Onkológiai Intézet-Urogenitális Tumorok és Klinikai Farmakológiai Osztály ( Site 4301)
Budapest, Pest County, Hungary
Rambam Health Care Campus-Oncology Division ( Site 3500)
Haifa, Israel
Hadassah Medical Center-Oncology ( Site 3504)
Jerusalem, Israel
Rabin Medical Center ( Site 3502)
Petah Tikva, Israel
Sheba Medical Center - Oncology Division ( Site 3501)
Ramat Gan, Israel
Sourasky Medical Center ( Site 3503)
Tel Aviv, Israel
Nederlands Kanker Instituut - Antoni van Leeuwenhoek (NKI-AVL)-medical oncology ( Site 4402)
Amsterdam, North Holland, Netherlands
Erasmus Medisch Centrum ( Site 4401)
Rotterdam, South Holland, Netherlands
Auckland City Hospital ( Site 3700)
Auckland, New Zealand
Centrum Onkologii im. Prof. Franciszka Lukaszczyka-Ambulatorium Chemioterapii ( Site 4201)
Bydgoszcz, Kuyavian-Pomeranian Voivodeship, Poland
Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Oddzial Badan Wczesnych Faz ( Site 4200)
Warsaw, Masovian Voivodeship, Poland
Uniwersyteckie Centrum Kliniczne-Early Clinical Trials Unit ( Site 4202)
Gdansk, Pomeranian Voivodeship, Poland
Severance Hospital ( Site 3802)
Seoul, South Korea
Samsung Medical Center ( Site 3801)
Seoul, South Korea
Showing 40 of 51 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.